Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (125)

Search Parameters:
Keywords = eye care management

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
11 pages, 234 KiB  
Article
Improved Outcomes in Congenital Insensitivity to Pain with Anhidrosis (CIPA) via a Multidisciplinary Clinic Model
by Moshe Shmueli, Galina Ling, Siham Elamour, Yaron Weisel and Shalom Ben-Shimol
J. Clin. Med. 2025, 14(15), 5258; https://doi.org/10.3390/jcm14155258 - 24 Jul 2025
Viewed by 383
Abstract
Background: Congenital insensitivity to pain with anhidrosis (CIPA) is a rare genetic disorder, often leading to injuries and serious infections. In 2018, we established a multidisciplinary clinic (MDC) to provide structured, proactive care. We assessed the MDC’s impact on hospitalizations, surgeries, and [...] Read more.
Background: Congenital insensitivity to pain with anhidrosis (CIPA) is a rare genetic disorder, often leading to injuries and serious infections. In 2018, we established a multidisciplinary clinic (MDC) to provide structured, proactive care. We assessed the MDC’s impact on hospitalizations, surgeries, and infection rates. Methods: A retrospective study of genetically confirmed CIPA patients, treated from 2014 to 2024. Data from electronic medical records were compared between the pre-MDC (2014–2017) and post-MDC (2018–2024) periods. The core MDC team includes an infectious disease specialist, orthopedic surgeon, and nurses. The patients are stratified according to their carriage of resistant organisms and are managed using strict infection control measures. Follow-ups are scheduled routinely or as needed. Treatment is guided by clinical findings and culture results. Results: A total of 59 patients were included in the study. The baseline age did not differ significantly between the two periods. Hospitalization rates declined by 30.7% (from 57.7 to 40.0 per 1000 days), and clinic visits decreased by 42.9% (25.5 to 14.6). Overall surgical rates remained stable (2.8 to 2.7), with a 61.9% decrease in eye surgeries and a 130.5% increase in elective tooth extractions. Infection rates increased by 52% (from 6.6 to 10.1 per 1000 days). Conclusions: The implementation of the MDC bundle led to reduced hospitalizations, clinic visits, and eye surgeries, alongside the increased use of elective tooth extractions and culture testing. Closer monitoring and early infection management contributed to fewer severe complications. These findings support the value of structured, proactive multidisciplinary care in improving outcomes for children with CIPA. Full article
(This article belongs to the Section Clinical Pediatrics)
19 pages, 473 KiB  
Review
Update on Retinoblastoma Therapies
by Cristina A. Martínez Arce, Victor M. Villegas, Maura Di Nicola, Basil K. Williams and Timothy G. Murray
Medicina 2025, 61(7), 1219; https://doi.org/10.3390/medicina61071219 - 4 Jul 2025
Viewed by 565
Abstract
Retinoblastoma is a success story in pediatric oncology, evolving from life-saving interventions to approaches that preserve eyes and vision while minimizing complications. Initially managed with enucleation and radiotherapy, treatment now emphasizes eye preservation through chemotherapy as the cornerstone therapy. Various chemotherapy delivery methods—including [...] Read more.
Retinoblastoma is a success story in pediatric oncology, evolving from life-saving interventions to approaches that preserve eyes and vision while minimizing complications. Initially managed with enucleation and radiotherapy, treatment now emphasizes eye preservation through chemotherapy as the cornerstone therapy. Various chemotherapy delivery methods—including intravenous (IVC), intraarterial (IAC), intravitreal, intracameral, and periocular—offer flexibility in treatment. Studies show nearly 100% eye salvage rates for groups A–C. For advanced cases (groups D and E), IAC has achieved outcomes that were not possible before. Intravitreal injections, when performed safely, may help avoid enucleation and radiotherapy in advanced cases, preserving vision, even in complex scenarios, with vitreous seeding. Each strategy may be tailored to tumor and patient characteristics that may help optimize outcomes. Recent innovations like liquid biopsy, prenatal diagnosis, prognostic biomarkers, and new surgical methods, such as tylectomy and chemoplaque, are paving the way for more personalized care. While advanced extraocular or metastatic retinoblastoma remains challenging, these advancements underscore a shift towards better outcomes and individualized management. The future holds promise for refining treatment strategies to maximize eye and vision preservation while ensuring patient survival. Full article
(This article belongs to the Section Ophthalmology)
Show Figures

Figure 1

27 pages, 2478 KiB  
Article
Early Diabetic Retinopathy Detection from OCT Images Using Multifractal Analysis and Multi-Layer Perceptron Classification
by Ahlem Aziz, Necmi Serkan Tezel, Seydi Kaçmaz and Youcef Attallah
Diagnostics 2025, 15(13), 1616; https://doi.org/10.3390/diagnostics15131616 - 25 Jun 2025
Viewed by 577
Abstract
Background/Objectives: Diabetic retinopathy (DR) remains one of the primary causes of preventable vision impairment worldwide, particularly among individuals with long-standing diabetes. The progressive damage of retinal microvasculature can lead to irreversible blindness if not detected and managed at an early stage. Therefore, the [...] Read more.
Background/Objectives: Diabetic retinopathy (DR) remains one of the primary causes of preventable vision impairment worldwide, particularly among individuals with long-standing diabetes. The progressive damage of retinal microvasculature can lead to irreversible blindness if not detected and managed at an early stage. Therefore, the development of reliable, non-invasive, and automated screening tools has become increasingly vital in modern ophthalmology. With the evolution of medical imaging technologies, Optical Coherence Tomography (OCT) has emerged as a valuable modality for capturing high-resolution cross-sectional images of retinal structures. In parallel, machine learning has shown considerable promise in supporting early disease recognition by uncovering complex and often imperceptible patterns in image data. Methods: This study introduces a novel framework for the early detection of DR through multifractal analysis of OCT images. Multifractal features, extracted using a box-counting approach, provide quantitative descriptors that reflect the structural irregularities of retinal tissue associated with pathological changes. Results: A comparative evaluation of several machine learning algorithms was conducted to assess classification performance. Among them, the Multi-Layer Perceptron (MLP) achieved the highest predictive accuracy, with a score of 98.02%, along with precision, recall, and F1-score values of 98.24%, 97.80%, and 98.01%, respectively. Conclusions: These results highlight the strength of combining OCT imaging with multifractal geometry and deep learning methods to build robust and scalable systems for DR screening. The proposed approach could contribute significantly to improving early diagnosis, clinical decision-making, and patient outcomes in diabetic eye care. Full article
(This article belongs to the Section Machine Learning and Artificial Intelligence in Diagnostics)
Show Figures

Figure 1

18 pages, 319 KiB  
Review
Should We Fear Wipe-Out in Glaucoma Surgery?
by Marco Zeppieri, Ludovica Cannizzaro, Giuseppe Gagliano, Francesco Cappellani, Lorenzo Rapisarda, Alfonso Spinello, Antonio Longo, Andrea Russo and Alessandro Avitabile
Diagnostics 2025, 15(13), 1571; https://doi.org/10.3390/diagnostics15131571 - 20 Jun 2025
Viewed by 527
Abstract
Wipe-out is defined as a sudden, unexplained, and irreversible loss of residual central vision following glaucoma surgery, typically in eyes with advanced visual field damage and severely compromised optic nerves. The purpose of this review is to critically assess the current incidence, risk [...] Read more.
Wipe-out is defined as a sudden, unexplained, and irreversible loss of residual central vision following glaucoma surgery, typically in eyes with advanced visual field damage and severely compromised optic nerves. The purpose of this review is to critically assess the current incidence, risk factors, pathophysiological mechanisms, and clinical relevance of “wipe-out”, a rare but devastating complication of glaucoma surgery characterized by sudden, unexplained central vision loss postoperatively. A comprehensive literature review was conducted, analyzing key peer-reviewed studies from electronic databases (PubMed, Medline, and Google Scholar) published up to 2025. The data from the literature published prior to the year 2000 suggest that wipe-out incidences range broadly from <1% to 13%. Contemporary prospective studies and large-scale reviews indicate a significantly lower current incidence, frequently below 1%. Identified risk factors include severe preoperative visual field loss (especially split fixation), older age, immediate postoperative hypotony, and compromised optic nerve head perfusion. The proposed mechanisms involve acute vascular insults, ischemia–reperfusion injury, and accelerated apoptosis of already vulnerable retinal ganglion cells. Modern MIGS and refined trabeculectomy techniques exhibit notably lower wipe-out risks compared to historical data. The literature emphasizes preventive management, including careful patient selection, incremental intraocular pressure reduction, and minimally invasive anesthetic approaches. Although wipe-out syndrome represents a serious complication, its incidence in modern glaucoma surgery is minimal. The considerable benefits of contemporary surgical approaches—particularly MIGS—in preserving vision clearly outweigh this very low risk. Ophthalmologists should remain vigilant but confident in the safety and efficacy of modern glaucoma surgical techniques, emphasizing proactive intervention to prevent blindness rather than avoiding necessary surgery in consideration of the minimal risk of wipe-out. Full article
(This article belongs to the Special Issue Eye Disease: Diagnosis, Management, and Prognosis)
7 pages, 630 KiB  
Case Report
Rapidly Progressive Buccal Hematoma Following Local Anesthetic Injection: A Case Report
by Solon Politis, Dimitris Tatsis, Asterios Antoniou, Alexandros Louizakis and Konstantinos Paraskevopoulos
Reports 2025, 8(2), 88; https://doi.org/10.3390/reports8020088 - 5 Jun 2025
Viewed by 1035
Abstract
Background and Clinical Significance: Local anesthetic injections, routine in dental practice, ensure pain control during procedures like root canal treatments. Though generally safe, they can occasionally cause hematomas, localized blood accumulations in tissue planes. Rapidly expanding hematomas in the head and neck are [...] Read more.
Background and Clinical Significance: Local anesthetic injections, routine in dental practice, ensure pain control during procedures like root canal treatments. Though generally safe, they can occasionally cause hematomas, localized blood accumulations in tissue planes. Rapidly expanding hematomas in the head and neck are exceptionally rare but dangerous due to anatomical complexity, potentially threatening the airway. This case report emphasizes the critical need for the prompt recognition and management of such complications to prevent life-threatening outcomes, highlighting vigilance in routine dental procedures. Case Presentation: A 63-year-old male presented with rapidly enlarging right buccal swelling four hours post-local anesthetic injection for a root canal on a right maxillary molar. Examination showed warm, erythematous edema and buccal ecchymosis; a CT scan confirmed a 3.8 cm × 8.4 cm × 5.5 cm buccal space hematoma. His medical history revealed controlled type 2 diabetes and hyperlipidemia, and his coagulation was normal. Conservative management failed as the hematoma progressed, limiting mouth and eye opening. Urgent surgical decompression under general anesthesia evacuated clots and ligated facial and angular arteries. ICU monitoring ensured airway stability, with discharge on day three with antibiotics and follow-up. Conclusions: This case highlights the rare potential for dental anesthetic injections to cause rapidly progressive hematomas, requiring urgent surgical intervention and multidisciplinary care to prevent airway compromise. Early recognition, imaging, and decisive management are vital in achieving favorable outcomes in such serious complications. Full article
Show Figures

Figure 1

14 pages, 976 KiB  
Article
Sutureless Scleral-Fixated Soleko Fil Carlevale Intraocular Lens and Associated Pars Plana Vitrectomy in Aphakia Management: A National Multicenter Audit
by Lorena Ferrer-Alapont, Carolina Bernal-Morales, Manuel J. Navarro, Diego Ruiz-Casas, Claudia García-Arumí, Juan Manuel Cubero-Parra, Jose Vicente Dabad-Moreno, Daniel Velázquez-Villoria, Joaquín Marticorena, Julián Zarco-Bosquet, Félix Armada-Maresca, Cristina Irigoyen, Juan-Francisco Santamaría-Álvarez, Pablo Carnota-Méndez, Idaira Sánchez-Santos, Nuria Olivier-Pascual, Francisco Javier Ascaso and Javier Zarranz-Ventura
J. Clin. Med. 2025, 14(11), 3963; https://doi.org/10.3390/jcm14113963 - 4 Jun 2025
Viewed by 859
Abstract
Objective: The aim of this study was to evaluate the clinical outcomes of sutureless scleral-fixated (SSF) Soleko Fil Carlevale intraocular lens (SC-IOL) implants associated with pars plana vitrectomy (PPV) in patients with aphakia secondary to complicated cataract surgery or IOL luxation nationwide. Methods: [...] Read more.
Objective: The aim of this study was to evaluate the clinical outcomes of sutureless scleral-fixated (SSF) Soleko Fil Carlevale intraocular lens (SC-IOL) implants associated with pars plana vitrectomy (PPV) in patients with aphakia secondary to complicated cataract surgery or IOL luxation nationwide. Methods: A multicenter, national, retrospective study of 268 eyes (268 patients) which underwent simultaneous PPV and SC-IOL implantation was conducted. Demographics; ocular data; pre-surgical, surgical and post-surgical details; and refractive results were collected. Intra- and postoperative complications and management details were described. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central retinal thickness (CRT) were collected at 1 week and at 1, 3, 6 and 12 months post-surgery. Kaplan–Meier curves were constructed to assess the cumulative probability of postoperative BCVA, IOP levels, macular edema (ME) and corneal decompensation. Results: The cumulative probability of final VA ≤ 0.3 logMAR was 64.4% at 12 months follow-up. The probability of IOP > 21, ≥25 and ≥30 mmHg was 29.8%, 16.9% and 10.1%, respectively, and the cumulative probability of IOP-lowering treatment was 42.3% at 12 months. Glaucoma surgery was required in 3.7% of the eyes (10/268). The cumulative probability of postoperative ME development was 26.6% at 12 months, managed with topical treatment alone (73.5%) and intravitreal injections (26.5%). Corneal transplantation was required in 3.7% of the eyes (10/268). Conclusions: Sutureless scleral-fixated SC-IOL is an adequate therapeutic alternative in the management of aphakia with good visual results and an acceptable safety profile in routine clinical care. Longer-term studies are needed to evaluate its results and complications compared to other therapeutic alternatives. Full article
(This article belongs to the Section Ophthalmology)
Show Figures

Figure 1

13 pages, 539 KiB  
Review
Green Endoscopy: A Review of Global Perspectives on Environmental Sustainability of Gastrointestinal Endoscopy
by Adishwar Rao, Abdullah Sultany, Amlish Gondal, Raja Chandra Chakinala, Hareesha Rishab Bharadwaj, Saurabh Chandan, Hassam Ali, Sheza Malik, Saqr Alsakarneh and Dushyant Singh Dahiya
J. Clin. Med. 2025, 14(11), 3936; https://doi.org/10.3390/jcm14113936 - 3 Jun 2025
Viewed by 846
Abstract
Endoscopic procedures are the cornerstone of intervention in gastroenterology—from evaluating common illnesses to non-surgically managing complex diseases. Expectedly, these procedures are linked to greenhouse gas (GHG) emissions globally and contribute significantly to the global climate change crisis. Professional gastroenterology societies globally raise awareness [...] Read more.
Endoscopic procedures are the cornerstone of intervention in gastroenterology—from evaluating common illnesses to non-surgically managing complex diseases. Expectedly, these procedures are linked to greenhouse gas (GHG) emissions globally and contribute significantly to the global climate change crisis. Professional gastroenterology societies globally raise awareness of this evolving crisis and suggest specific measures to appropriately measure the burden contributed by endoscopy units and mitigate the environmental impact of this common clinical practice. To the unsuspecting eye, the solution to this crisis is relatively simple: decrease the utilization of endoscopic procedures. However, the dependence of modern medicine on these procedures, both diagnostically and therapeutically, makes it significantly more challenging to reduce their utilization. Instead, a structured approach to systematically consider the specific indications for each procedure, minimize waste generation, promote recycling of waste products, and limit the number of repeat endoscopies until clinically necessary may be more pragmatic to reduce GHG emissions globally. In this narrative review, we discuss the perspectives of global gastroenterology societies on sustainable or “green” endoscopy and summarize their recommendations to aid the day-to-day gastroenterologist in making their contribution to environmental sustainability while providing optimal care to their patients. Full article
(This article belongs to the Section Gastroenterology & Hepatopancreatobiliary Medicine)
Show Figures

Figure 1

18 pages, 1647 KiB  
Review
The Evolving Landscape of Radiomics in Gliomas: Insights into Diagnosis, Prognosis, and Research Trends
by Mehek Dedhia and Isabelle M. Germano
Cancers 2025, 17(9), 1582; https://doi.org/10.3390/cancers17091582 - 6 May 2025
Viewed by 901
Abstract
Gliomas are the most prevalent and aggressive form of primary brain tumors. The clinical challenge in managing patients with this disease revolves around the difficulty of diagnosis, both at onset and during treatment, and the scarcity of prognostic outcome indicators. Radiomics involves the [...] Read more.
Gliomas are the most prevalent and aggressive form of primary brain tumors. The clinical challenge in managing patients with this disease revolves around the difficulty of diagnosis, both at onset and during treatment, and the scarcity of prognostic outcome indicators. Radiomics involves the extraction of quantitative features from medical images with the help of artificial intelligence, positioning it as a promising tool to be integrated into the care of glioma patients. Using data from 52 studies and 12,482 patients over two years, this review explores how radiomics can enhance the initial diagnosis of gliomas, especially helping to differentiate treatment stages that may be difficult for the human eye to do otherwise. Radiomics has also been able to identify patient-specific tumor molecular signatures for targeted treatments without the need for invasive surgical biopsy. Such an approach could lead to earlier interventions and more precise individualized therapies that are tailored to each patient. Additionally, it could be integrated into clinical practice to improve longitudinal diagnosis during treatment and predict tumor recurrence. Finally, radiomics has the potential to predict clinical outcomes, helping both patients and providers set realistic expectations. While this field is continuously evolving, future research should conduct such studies in larger, multi-institutional cohorts to enhance generalizability and applicability in clinical practice and focus on combining radiomics with other modalities to improve its predictive accuracy and clinical utility. Full article
(This article belongs to the Special Issue Radiomics in Cancer)
Show Figures

Figure 1

34 pages, 558 KiB  
Review
Emerging Trends and Management for Sjögren Syndrome-Related Dry Eye Corneal Alterations
by Maria Letizia Salvetat, Francesco Pellegrini, Fabiana D’Esposito, Mutali Musa, Daniele Tognetto, Rosa Giglio, Roberta Foti, Caterina Gagliano and Marco Zeppieri
Appl. Sci. 2025, 15(9), 5076; https://doi.org/10.3390/app15095076 - 2 May 2025
Viewed by 1249
Abstract
Background: Sjögren’s syndrome (SS) is a systemic autoimmune condition marked by significant dry eye disease (DED), leading to considerable corneal changes. These modifications, encompassing punctate epithelial erosions, chronic epithelial abnormalities, and corneal ulcers, significantly impact eyesight and quality of life. Progress in comprehending [...] Read more.
Background: Sjögren’s syndrome (SS) is a systemic autoimmune condition marked by significant dry eye disease (DED), leading to considerable corneal changes. These modifications, encompassing punctate epithelial erosions, chronic epithelial abnormalities, and corneal ulcers, significantly impact eyesight and quality of life. Progress in comprehending the corneal pathophysiology associated with SS has prompted innovative diagnostic and treatment approaches. Aim: This narrative review aims to examine developing trends in the pathogenesis, diagnostic methods, and treatment strategies for Sjögren’s syndrome-associated corneal changes. Methods: The study was based on a narrative review of the current literature available on PubMed and Cochrane from Jan 2000 to December 2024. Results: Corneal changes associated with Sjögren’s syndrome result from a multifactorial interaction of ocular surface inflammation, tear film instability, and epithelium degradation. Recent research underscores the significance of immune-mediated pathways, such as T-cell-induced inflammation and cytokine dysregulation, as crucial factors in corneal disease. Innovations in diagnostic instruments, including in vivo confocal microscopy and tear proteomics, provide earlier and more accurate identification of subclinical alterations in the corneal epithelium and stroma. Therapeutic developments concentrate on meeting the specific requirements of SS-related DED. Biological treatments, especially tailored inhibitors of interleukin-6 and tumor necrosis factor-alpha, show potential in mitigating inflammation and facilitating epithelial repair. Moreover, regenerative approaches, such as autologous serum tears and mesenchymal stem cell therapies, provide innovative methods to repair ocular surface integrity. Advanced drug delivery technologies, including nanoparticle-loaded eye drops, enhance bioavailability and therapeutic efficacy. Conclusion: Recent developments in comprehending SS-related corneal changes have transformed the management approach to precision medicine. The combination of improved diagnostics and innovative therapy approaches offers potential for reducing disease progression, maintaining corneal health, and enhancing patient outcomes. Subsequent investigations ought to concentrate on enhancing these tactics and examining their long-term safety and effectiveness. Clinicians and researchers must adopt these developments to successfully tackle the difficulties of SS-related corneal illness, providing hope for improved care and higher quality of life for those affected. Full article
(This article belongs to the Special Issue Trends and Prospects in Retinal and Corneal Diseases)
14 pages, 250 KiB  
Review
Unraveling the Mechanisms, Clinical Impact, Comparisons, and Safety Profiles of Slow-Release Therapies in Glaucoma
by Marco Zeppieri, Caterina Gagliano, Daniele Tognetto, Mutali Musa, Federico Bernardo Rossi, Angelo Greggio, Giuliano Gualandi, Alessandro Galan and Silvia Babighian
Pharmaceutics 2025, 17(5), 580; https://doi.org/10.3390/pharmaceutics17050580 - 28 Apr 2025
Viewed by 514
Abstract
Glaucoma, a primary cause of irreversible blindness, is most effectively managed by reducing intraocular pressure (IOP). Topical eye drops, which are conventional treatments, frequently encounter constraints regarding patient compliance, inconsistent dosage, and tolerability. Slow-release drug delivery systems have emerged as a promising innovation [...] Read more.
Glaucoma, a primary cause of irreversible blindness, is most effectively managed by reducing intraocular pressure (IOP). Topical eye drops, which are conventional treatments, frequently encounter constraints regarding patient compliance, inconsistent dosage, and tolerability. Slow-release drug delivery systems have emerged as a promising innovation in response to these challenges. The objective of these systems is to enhance the efficacy of treatment and patient compliance by ensuring the consistent and sustained delivery of therapeutic agents over extended periods. Implantable devices, injectable formulations, and external applications are all categorized as slow-release therapies. By delivering medication directly to the target tissues in a controlled manner, these technologies have the potential to circumvent common issues associated with traditional regimens, such as forgotten doses or improper administration. These systems have been shown to obtain clinically meaningful reductions in IOP in studies, with some demonstrating efficacy that is comparable to that of established daily topical treatments. Despite their potential, slow-release therapies encounter obstacles that necessitate resolution. Potential complications during implantation or removal, long-term biocompatibility, and the cost of treatment are all areas of concern. Furthermore, further investigation is required to comprehensively assess their relative economic feasibility, patient acceptability, and long-term safety profiles in comparison to conventional treatments. This review summarizes the most recent findings in the scientific literature, underlining the role and possible limits of slow-release therapies in glaucoma with the aim of offering a comprehensive understanding of their potential clinical applications and challenges. This emphasizes the potential for these innovations to revolutionize care by addressing current knowledge gaps, while also emphasizing the areas in which further development and research are required. Full article
(This article belongs to the Special Issue Drug Delivery Systems for Ocular Diseases)
24 pages, 4123 KiB  
Article
Developing a Chromatographic Method for Quantifying Latanoprost and Related Substances in Glaucoma Treatments
by Katarzyna Asendrych-Wicik, Katarzyna Malik and Magdalena Markowicz-Piasecka
Pharmaceuticals 2025, 18(5), 619; https://doi.org/10.3390/ph18050619 - 24 Apr 2025
Viewed by 1054
Abstract
Background/Objectives: Latanoprost is a leading active pharmaceutical ingredient belonging to the synthetic prostaglandin F2α analogs, widely used as a first-line treatment for open-angle glaucoma and increased intraocular pressure. This study addresses the critical need for an accurate and precise chromatographic method that [...] Read more.
Background/Objectives: Latanoprost is a leading active pharmaceutical ingredient belonging to the synthetic prostaglandin F2α analogs, widely used as a first-line treatment for open-angle glaucoma and increased intraocular pressure. This study addresses the critical need for an accurate and precise chromatographic method that is capable of simultaneously quantifying latanoprost and six latanoprost-related substances in antiglaucoma eye drops. This will be crucial for patient safety and treatment efficacy. This method enables the separation of latanoprost isomers, (15S)-latanoprost, latanoprost enantiomer, and 5,6-trans latanoprost from latanoprost signal. Furthermore, it is specific for the well-known latanoprost degradants—the major latanoprost acid and the minor 15-ketolatanoprost—as well as synthetic derivatives, such as triphenylphosphine oxide (TPPO) and propan-2-yl 5-(diphenylphosphoryl)pentanoate (IDPP). Using forced degradation studies using high temperatures, UV light, alkalis, acids, and oxidizing agents, the degradation profiles of the drugs were characterized and the method’s stability-indicating power was confirmed. Methods: Separation was achieved on a stationary combined system comprising chiral and cyano columns. Reverse-phase gradient elution and UV 210 nm detection were employed. The novel method was validated according to the European Medicines Agency International Council for Harmonisation Q2 Validation of analytical procedures—Scientific guideline. Results: The method was shown to be linear in the range of 40–60 µg/mL for latanoprost and 0.05–2.77 µg/mL for related substances, confirmed by a correlation coefficient of r = 0.999. Recoveries for latanoprost were obtained within the range of 98.0–102.0% for assays and 90.0–110.0% for impurities. The detection and quantification limits for latanoprost were 0.025 µg/mL and 0.35 µg/mL, respectively. Conclusions: The analytical procedure developed is adequately sensitive, precise, and accurate compared to existing methods. The method can be reliably used to control the critical quality attributes of low-dose latanoprost products, ensuring their required high pharmaceutical quality, which translates into improvements in patient care. This advancement holds significant implications for enhancing the therapeutic management of glaucoma, ensuring drug safety and efficacy. Full article
(This article belongs to the Special Issue Advances in Drug Analysis and Drug Development)
Show Figures

Graphical abstract

33 pages, 4263 KiB  
Review
Iatrogenic Ocular Surface Complications After Surgery for Ocular and Adnexal Tumors
by Maria Angela Romeo, Andrea Taloni, Massimiliano Borselli, Alessandra Di Maria, Alessandra Mancini, Vincenzo Mollace, Giovanna Carnovale-Scalzo, Vincenzo Scorcia and Giuseppe Giannaccare
Cancers 2025, 17(9), 1384; https://doi.org/10.3390/cancers17091384 - 22 Apr 2025
Viewed by 1295
Abstract
Background/Objectives: The management of ocular tumors often necessitates surgery, either alone or in combination with radiotherapy, chemotherapy, or other modalities. While crucial for tumor control, these treatments can significantly impact the ocular surface, leading to both acute and chronic complications. This review examines [...] Read more.
Background/Objectives: The management of ocular tumors often necessitates surgery, either alone or in combination with radiotherapy, chemotherapy, or other modalities. While crucial for tumor control, these treatments can significantly impact the ocular surface, leading to both acute and chronic complications. This review examines iatrogenic ocular surface diseases resulting from oncologic interventions, emphasizing their pathophysiology, diagnostic challenges, and management strategies. Methods: A literature review was conducted to identify studies on iatrogenic ocular surface complications associated with ocular tumor treatments. Results: Ocular surface complications include direct damage from surgical manipulation, leading to corneal opacities and persistent epithelial defects, as well as dry eye disease secondary to postoperative chemosis. These disruptions may progress to more severe conditions such as keratopathy, corneal ulcers, limbal stem cell deficiency, and stromal scarring, further impairing visual function. Structural alterations contribute to eyelid malpositions—including ectropion, entropion, round eye, and lagophthalmos—which exacerbate exposure-related damage and ocular surface instability. In cases of uveal melanomas, the exposure of episcleral brachytherapy plaques can induce chronic conjunctival irritation, promoting adhesion formation and symblepharon. Surgical interventions disrupt ocular surface homeostasis, while radiotherapy and chemotherapy exacerbate these effects through cytotoxic and inflammatory mechanisms. Conclusions: Preventing and managing iatrogenic ocular surface complications require a multidisciplinary approach involving early diagnosis, personalized treatment strategies, and targeted postoperative care. Comprehensive pre- and postoperative planning is essential to optimize both visual function and long-term ocular surface integrity, ultimately ensuring a balance between oncologic control with functional and aesthetic preservation. Full article
(This article belongs to the Section Cancer Therapy)
Show Figures

Figure 1

16 pages, 276 KiB  
Review
Current Treatment Paradigms for Advanced Melanoma with Brain Metastases
by Elisabetta Bonzano, Stefania Barruscotti, Silvia Chiellino, Benedetta Montagna, Chiara Bonzano, Ilaria Imarisio, Sara Colombo, Francesco Guerrini, Jessica Saddi, Salvatore La Mattina, Carlo Francesco Tomasini, Giannantonio Spena, Paolo Pedrazzoli and Andrea Lancia
Int. J. Mol. Sci. 2025, 26(8), 3828; https://doi.org/10.3390/ijms26083828 - 18 Apr 2025
Viewed by 1147
Abstract
The therapeutic management of melanoma brain metastases has undergone a profound revolution during recent decades. Optimal integration of systemic therapies with local treatments seems to represent the strategy to pursue in order to maximize clinical outcomes, stressing the need for real multidisciplinary care [...] Read more.
The therapeutic management of melanoma brain metastases has undergone a profound revolution during recent decades. Optimal integration of systemic therapies with local treatments seems to represent the strategy to pursue in order to maximize clinical outcomes, stressing the need for real multidisciplinary care in this setting of patients. However, the current approach in the clinics does not necessarily reflect what the current guidelines state, and several pending issues are present, from the ideal therapeutic sequence between stereotactic radiosurgery (SRS) and drug administration to the current role of surgery and whole brain radiotherapy (WBRT), all of which need to be addressed. This narrative review aims to provide practical help for navigating the current controversies, with an eye towards possible future advancements in the field, which could help to obtain a comprehensive molecular characterization of the tumor and a more personalized patient-centered therapeutic approach. Full article
(This article belongs to the Special Issue Advances in Melanoma and Skin Cancers: 2nd Edition)
13 pages, 1702 KiB  
Article
Ten-Year Results After Canaloplasty and Phacocanaloplasty
by Hanga Beres, Bendegúz Gyarmati, Simona Gurzu and Gabor Bernd Scharioth
J. Clin. Med. 2025, 14(7), 2481; https://doi.org/10.3390/jcm14072481 - 4 Apr 2025
Viewed by 539
Abstract
Background/Objectives: To evaluate the long-term efficacy and safety of canaloplasty and phacocanaloplasty in patients with primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PEXG). Methods: This retrospective observational study included 85 patients with POAG and PEXG who underwent canaloplasty (group 1) or [...] Read more.
Background/Objectives: To evaluate the long-term efficacy and safety of canaloplasty and phacocanaloplasty in patients with primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PEXG). Methods: This retrospective observational study included 85 patients with POAG and PEXG who underwent canaloplasty (group 1) or phacocanaloplasty (group 2). Every patient had complete medical records over a 10-year follow-up period. The primary endpoints were the pressure-lowering and drug-sparing effects. The secondary endpoints were intra- and postoperative complications as well as the need for additional surgical interventions. Results: In group 1, the mean baseline intraocular pressure (IOP) of 22.1 ± 0.9 mmHg was reduced to 15.3 ± 0.5 mmHg, 15.7 ± 0.5 mmHg, and 15.9 ± 0.7 mmHg at 1, 5, and 10 years, respectively. The mean medication use decreased from 2.4 ± 1.0 before surgery to 0.1 ± 0.5, 0.8 ± 1.1, and 1.4 ± 1.3 at 1,5, and 10 years, respectively. In group 2, IOP was reduced from 20.4 ± 1.5 to 15.6 ± 1.0, 14.3 ± 0.8, and 14.2 ± 1.2 at 1, 5, and 10 years, respectively. The mean medication use dropped from 2.4 ± 1 to 0.3 ± 0.9, 0.9 ± 1.4, and 0.8 ± 1.1 at 1,5, and 10 years, respectively. Goniopuncture was performed postoperatively in nine cases (13.9%) within the initial 3 months due to IOP spikes (POAG n = 6, PEXG n = 3). Patients with PEXG had a significantly higher likelihood of requiring re-operation (HR = 5.11, HR = 5.11, 95% CI 1.05–24.74, p = 0.043). No serious complications were observed. Conclusions: Canaloplasty is a safe and effective procedure for lowering IOP in eyes with POAG and PEXG, achieving approximately a 30% reduction in IOP. PEXG patients are likelier to have IOP spikes in the late postoperative period therefore careful monitoring and management is required. Full article
(This article belongs to the Section Ophthalmology)
Show Figures

Figure 1

23 pages, 1237 KiB  
Review
Risk of Permanent Corneal Injury in Microgravity: Spaceflight-Associated Hazards, Challenges to Vision Restoration, and Role of Biotechnology in Long-Term Planetary Missions
by Jainam Shah, Joshua Ong, Ryung Lee, Alex Suh, Ethan Waisberg, C. Robert Gibson, John Berdahl and Thomas H. Mader
Life 2025, 15(4), 602; https://doi.org/10.3390/life15040602 - 4 Apr 2025
Cited by 2 | Viewed by 1038
Abstract
Human space exploration presents an unparalleled opportunity to study life in extreme environments—but it also exposes astronauts to physiological stressors that jeopardize key systems like vision. Corneal health, essential for maintaining precise visual acuity, is threatened by microgravity-induced fluid shifts, cosmic radiation, and [...] Read more.
Human space exploration presents an unparalleled opportunity to study life in extreme environments—but it also exposes astronauts to physiological stressors that jeopardize key systems like vision. Corneal health, essential for maintaining precise visual acuity, is threatened by microgravity-induced fluid shifts, cosmic radiation, and the confined nature of spacecraft living environments. These conditions elevate the risk of corneal abrasions, infections, and structural damage. In addition, Spaceflight-Associated Neuro-Ocular Syndrome (SANS)—while primarily affecting the posterior segment—has also been potentially linked to anterior segment alterations such as corneal edema and tear film instability. This review examines these ocular challenges and assesses current mitigation strategies. Traditional approaches, such as terrestrial eye banking and corneal transplantation, are impractical for spaceflight due to the limited viability of preserved tissues, surgical complexities, anesthetic risks, infection potential, and logistical constraints. The paper explores emerging technologies like 3D bioprinting and stem cell-based tissue engineering, which offer promising solutions by enabling the on-demand production of personalized corneal constructs. Complementary advancements, including adaptive protective eyewear, bioengineered tear substitutes, telemedicine, and AI-driven diagnostic tools, also show potential in autonomously managing ocular health during long-duration missions. By addressing the complex interplay of environmental stressors and biological vulnerabilities, these innovations not only safeguard astronaut vision and mission performance but also catalyze new pathways for regenerative medicine on Earth. The evolution of space-based ophthalmic care underscores the dual impact of space medicine investments across planetary exploration and terrestrial health systems. Full article
Show Figures

Figure 1

Back to TopTop